Compare Figma Inc. Class A Common Stock (FIG) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figma Inc. Class A Common Stock vs Kymera Therapeutics Inc. Common Stock — how do they compare? Figma Inc. Class A Common Stock trades at $21.29 (market cap $11.45B), while Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B). The key difference: Figma Inc. Class A Common Stock is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Figma Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figma Inc. Class A Common Stock for 0 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| FIG | KYMR | |
|---|---|---|
Market Cap | $11.45B | $8.88B |
Volume | 12,424,893 | 1,028,790 |
Sector | Technology | Health |
52-Week High | $63.82 | $127.31 |
52-Week Low | $16.84 | $55.80 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $9.85B | $8.27B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Figma Inc. Class A Common Stock
Figma, Inc. is a US software company that operates a collaborative interface design and product development platform used by design and engineering teams to create, prototype, and build digital products.
Read more on FIG →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
